On July 15, a coalition of leading healthcare organizations, including the American College of Obstetricians and Gynecologists (ACOG), the Society for Women’s Health Research (SWHR), and the Women First Research Coalition (WFRC), formally introduced the National Strategy to Close the Women’s Health Gap. This comprehensive policy framework issues a direct call to the United States Congress to authorize a $20 billion investment over the next decade to fundamentally transform the landscape of women’s health research, clinical care, and long-term health outcomes. The strategy represents one of the most ambitious legislative and medical initiatives in recent history, aiming to rectify decades of systemic underfunding and scientific oversight regarding the unique physiological and medical needs of women.
The proposal has garnered immediate and widespread support from across the medical community. The Endocrine Society, alongside more than 20 other professional medical associations, patient advocacy groups, and research institutions, has officially endorsed the strategy. These organizations argue that the current state of women’s health in the United States is at a critical juncture, where scientific discovery has not yet caught up with the demographic reality that women constitute more than half of the national population.
A Legacy of Exclusion and the Need for Reform
To understand the necessity of the National Strategy to Close the Women’s Health Gap, it is essential to examine the historical context of medical research in the United States. For much of the 20th century, the "male-as-default" model dominated clinical science. This was codified in part by a 1977 Food and Drug Administration (FDA) policy that excluded women of childbearing age from Phase I and Phase II clinical trials, largely due to concerns over potential fetal exposure and the perceived "complications" of fluctuating hormonal cycles.
A significant turning point occurred in 1993 with the passage of the NIH Revitalization Act. This landmark legislation mandated the inclusion of women and minority groups in clinical research funded by the National Institutes of Health (NIH). While the 1993 Act successfully increased the number of women participating in trials, experts argue that "inclusion" has not translated into "analysis." Many studies still fail to report sex-disaggregated data, meaning the specific ways in which treatments affect women differently than men often remain unexamined.
The National Strategy identifies that while the 1993 law was a vital first step, the "health gap" persists because research infrastructure, funding priorities, and clinical practice have not evolved to address the complexities of women’s health across the lifespan. The strategy asserts that women’s health must be viewed as more than just reproductive health; it encompasses autoimmune diseases, cardiovascular health, neurological conditions, and the profound influence of the endocrine system.
The Role of Hormonal Research in Women’s Health
A central pillar of the new strategy is the advancement of endocrine and hormonal research. Because hormones regulate nearly every biological process—from metabolism and bone density to cognitive function and cardiovascular health—understanding their specific behavior in the female body is paramount.
Nanette Santoro, MD, President of the Endocrine Society, emphasized this point during the announcement. "Because hormones influence nearly every aspect of women’s health, advancing research in this area has the potential to improve millions of lives," Dr. Santoro stated. She noted that the Endocrine Society is particularly encouraged by the strategy’s emphasis on data-driven clinical care. Hormonal transitions, such as puberty, pregnancy, and menopause, are not merely reproductive milestones but are periods of significant physiological change that can influence the onset of chronic diseases.
For example, women are significantly more likely than men to develop autoimmune disorders, such as lupus or rheumatoid arthritis, and are at a higher risk for certain types of thyroid disease. The National Strategy argues that a dedicated $20 billion investment would allow researchers to investigate the "why" behind these disparities, leading to more targeted and effective interventions.
Five Key Priorities for National Investment
The National Strategy to Close the Women’s Health Gap is structured around five core priorities designed to create a sustainable ecosystem for medical advancement. While the full technical details of the framework are being presented to lawmakers, the broad objectives include:
- Direct Research Funding: Allocating substantial portions of the $20 billion to NIH and other federal agencies to specifically study conditions that are either unique to women, more prevalent in women, or manifest differently in women.
- Modernizing Policy and Regulation: Updating federal guidelines to ensure that sex is considered a biological variable in all stages of research, from basic laboratory science to late-stage clinical trials.
- Workforce Development: Investing in the "people power" behind the science. This includes grants and incentives for researchers specializing in women’s health and training for primary care physicians to better recognize and treat sex-specific symptoms.
- Data Standardization: Improving the collection and analysis of health data to ensure that outcomes are tracked by sex, age, and ethnicity, allowing for a more nuanced understanding of health disparities.
- Access to Evidence-Based Care: Ensuring that scientific breakthroughs are translated into clinical practice quickly and that all women, regardless of socioeconomic status, have access to the resulting treatments.
Sandra E. Brooks, MD, MBA, FACOG, and Chief Executive Officer of ACOG, highlighted the importance of the workforce component. "Closing the women’s health gap requires not only funding research, but also investment in the people who conduct that research and those who translate research findings and discoveries into better patient care," Dr. Brooks said. She noted that strengthening the clinical workforce is the only way to ensure that innovation actually reaches the patient’s bedside.
Supporting Data and the Economic Case for Investment
The call for $20 billion is supported by data suggesting that the "women’s health gap" is not only a medical crisis but an economic one. A recent report by the McKinsey Health Institute estimated that addressing the women’s health gap could potentially boost the global economy by $1 trillion annually by 2040. This economic gain would stem from increased labor force participation, fewer sick days, and longer, more productive lives for women.
In the United States, specific health metrics underscore the urgency. Maternal mortality rates in the U.S. remain the highest among developed nations, with significant disparities affecting Black and Indigenous women. Furthermore, cardiovascular disease remains the leading cause of death for women, yet women are less likely than men to receive standard diagnostic tests or life-saving interventions following a heart attack.
The Society for Women’s Health Research (SWHR) points out that conditions like endometriosis, which affects an estimated 1 in 10 women, often take an average of seven to ten years to diagnose. The National Strategy posits that with adequate funding, these diagnostic delays can be eliminated through the development of better screening tools and increased provider education.
A Coalition of Advocacy
The breadth of the endorsement list for the National Strategy reflects the intersectional nature of women’s health. The coalition includes a diverse array of organizations, ranging from the American Heart Association and the Arthritis Foundation to the Black Women’s Health Imperative and the Women’s Alzheimer’s Movement at Cleveland Clinic.
The inclusion of organizations like UsAgainstAlzheimer’s and the National MS Society is particularly telling. Women represent nearly two-thirds of Americans living with Alzheimer’s disease and are three times more likely than men to be diagnosed with multiple sclerosis (MS). By bringing these disparate groups together under a single strategy, ACOG, SWHR, and WFRC hope to present a unified front to Congress, demonstrating that women’s health is a multifaceted issue that touches every branch of medicine.
Kathryn Schubert, MPP, CAE, President and CEO of SWHR, noted that the persistence of the health gap is a policy failure that can be corrected. "The women’s health gap has persisted for far too long," Schubert said. "This strategy offers Congress a roadmap to improve health outcomes, drive innovation, and build a healthier future for women, families, and communities."
Implications and Future Outlook
If adopted by Congress, the National Strategy to Close the Women’s Health Gap would mark the most significant federal commitment to women’s medicine since the early 1990s. The proposed $20 billion over 10 years would provide the stability needed for long-term longitudinal studies, which are essential for understanding how health changes as women age.
The strategy also aims to address the "implementation gap"—the delay between a scientific discovery and its widespread use in doctor’s offices. By focusing on evidence-based care and clinical guidelines, the strategy seeks to ensure that a woman in a rural clinic receives the same high-standard, sex-specific care as a woman at a major urban research hospital.
As the proposal moves to the legislative stage, the endorsing organizations are urging a non-partisan approach. They argue that the health of women is foundational to the health of the nation’s families and its economy. The coming months will likely see increased advocacy on Capitol Hill as these professional societies and patient groups work to turn this strategic framework into funded reality.
The National Strategy to Close the Women’s Health Gap stands as a definitive statement from the medical community: the era of treating women as "smaller men" in medical research must end. Through coordinated investment and a commitment to scientific rigor, the coalition aims to ensure that the next generation of women benefits from a healthcare system designed with their specific biology in mind.
